Holoprosencephaly 9 (HPE9, GLI2-Related Holoprosencephaly): Comprehensive Research Report

1. Disease Information

Overview: Holoprosencephaly 9 (HPE9) is one of the numbered genetic subtypes of holoprosencephaly (HPE), the most common structural malformation of the developing forebrain in humans, caused by heterozygous mutations in GLI2 (GLI-Kruppel family member 2), a zinc-finger transcription factor that mediates Sonic Hedgehog (SHH) signaling. HPE9 is defined by a wide phenotypic spectrum — from frank forebrain non-cleavage (classic HPE) at the severe end, to an entirely distinct, more common presentation of pituitary anomalies, postaxial polydactyly, and subtle midfacial features without any brain cleavage defect at the milder end OMIM #610829; PMID:14581620. Because of this, the field has moved toward viewing GLI2 pathogenic variants as causing a phenotype distinct from classic HPE rather than "true" holoprosencephaly in most patients — GeneReviews notes GLI2 variants more often produce "pituitary anomalies, polydactyly, and subtle facial features (sometimes similar to HPE facial features)" than overt HPE (GeneReviews: Holoprosencephaly Overview, NBK1530). The milder, non-HPE end of the spectrum is now separately cataloged as Culler-Jones syndrome (CJS; OMIM #615849) — postaxial polydactyly–anterior pituitary anomalies–facial dysmorphism syndrome — caused by the same gene.

Key identifiers: - OMIM: #610829 (HPE9, phenotype); 165230 (GLI2, gene) - Related OMIM phenotype: #615849 (Culler-Jones syndrome, allelic disorder) - Gene: GLI2, HGNC:4318, chromosome 2q14.2, NCBI Gene ID 2735/2736 region - MONDO: A MONDO term for "holoprosencephaly 9" exists (indexed by NORD's Mondo-disease pages and ClinVar cross-references) but the exact MONDO CURIE could not be independently confirmed via the search tools used in this session — verify locally with an OAK lookup (e.g., runoak -i sqlite:obo:mondo search "holoprosencephaly 9") before use in curation. - Orphanet: HPE is cataloged generally as ORPHA:2162 (Holoprosencephaly); GLI2-specific HPE9 subtype entries exist in Orphanet's gene-disease association tables. - ICD-10: Q04.2 (Holoprosencephaly, general code; no HPE9-specific ICD-10/11 code exists) - Inheritance database cross-refs:* ClinVar aggregates GLI2 variants under "Holoprosencephaly 9" (e.g., RCV000030728).

Synonyms: HPE9; GLI2-related holoprosencephaly; Holoprosencephaly, GLI2-associated; (allelic, milder disorder) Culler-Jones syndrome; postaxial polydactyly–anterior pituitary anomalies–facial dysmorphism syndrome.

Evidence basis: Information is derived predominantly from aggregated case-series/cohort resources (OMIM, Orphanet, GeneReviews, ClinVar) built from published human case reports and cohort studies (not raw EHR data). The largest primary literature sources are multi-family cohort papers (e.g., Roessler et al. 2003, Bertolacini et al. 2012, Corder et al. 2022) rather than large-scale registries, reflecting HPE9's rarity.

2. Etiology

Disease causal factors — genetic: HPE9 is caused by heterozygous, typically loss-of-function, mutations in GLI2 (chromosome 2q14.2), a primary transcriptional effector of SHH signaling in the developing forebrain, face, and pituitary. Roessler et al. (2003) first established the disease-gene link, reporting "loss-of-function mutations in the human GLI2 gene are associated with a distinctive phenotype (within the HPE spectrum)... characterized by defective anterior pituitary formation and pan-hypopituitarism, with or without overt forebrain cleavage abnormalities, and HPE-like midfacial hypoplasia" PMID:14581620, PNAS 100(23):13424-13429, 2003.

Mutation spectrum includes nonsense, frameshift, splice-site, and missense variants, as well as contiguous gene deletions encompassing GLI2 (e.g., a 1.3 Mb 2q14 deletion producing a mild HPE-spectrum phenotype with heterotaxy, PMID:22106008). Truncating variants that remove the C-terminal transcriptional activator domain are the best-characterized loss-of-function class and are more strongly associated with pituitary anomalies and polydactyly than missense/zinc-finger variants (Corder et al. 2022, AJMG-A, "Truncating and zinc-finger variants in GLI2 are associated with hypopituitarism").

Relative contribution among HPE genes: The four major HPE genes (SHH, ZIC2, SIX3, TGIF1) together account for point mutations/microrearrangements in ~27% of isolated HPE cases (SHH ~12%, ZIC2 ~9%, SIX3 ~5%, TGIF1 ~1%). GLI2 and PTCH1 are "minor" genes, individually contributing <1% of classic HPE, though GLI2 is disproportionately represented among patients ascertained for the pituitary-anomaly/polydactyly phenotype rather than classic HPE — in one screened cohort of ~400 individuals with HPE-spectrum features, roughly 28% carried a GLI2 variant of some kind (most benign/uncertain significance; a minority pathogenic) (Bertolacini et al. 2012, PMID:21204792).

Genetic risk factors: - Heterozygous pathogenic/likely pathogenic GLI2 variants (nonsense, frameshift, splice, deletion; some missense in zinc-finger or activator domains) - De novo occurrence in many probands, but familial transmission with incomplete penetrance is common — a hallmark of GLI2-HPE - No established polygenic/susceptibility-locus modifiers specific to GLI2-HPE beyond the general HPE genetic-modifier literature (e.g., variants in other SHH-pathway genes can act as "second hits" in digenic-like models, per the broader HPE genotype-phenotype literature)

Environmental risk factors (relevant to the broader HPE spectrum, and shown experimentally to interact with Gli2 dosage): - Maternal pregestational diabetes — the single most robust environmental HPE risk factor, conferring >10-fold increased risk, with HPE occurring in ~1–2% of diabetic pregnancies; proposed mechanism involves oxidative stress and disrupted neural crest migration. - Retinoic acid excess — teratogenic in animal models via SHH pathway gene misregulation. - Cholesterol biosynthesis inhibitors (e.g., statins) and metabolic disorders of cholesterol synthesis (Smith-Lemli-Opitz syndrome, DHCR7) — cholesterol is required for SHH ligand post-translational modification and pathway activity. - Maternal alcohol exposure — a mouse study specifically demonstrates Gli2 gene-dosage × ethanol interaction: "The Teratogenic Effects of Prenatal Ethanol Exposure Are Exacerbated by Sonic Hedgehog or Gli2 Haploinsufficiency in the Mouse" (PMC3929747), directly demonstrating a gene-environment interaction relevant to GLI2 haploinsufficiency in humans.

Protective factors: No specific protective genetic or environmental factors for GLI2-HPE are established in the literature reviewed; general HPE literature does not identify protective alleles analogous to those in other Mendelian disorders.

Gene-environment interactions: The mouse Gli2 haploinsufficiency/ethanol model (above) and a separate mouse study on "Gli2 gene-environment interactions contribute to the etiological complexity of holoprosencephaly" (PMID:27585885; PMC5117230) provide the strongest direct mechanistic evidence: mice heterozygous for a Gli2 null allele are phenotypically normal at baseline but show markedly increased penetrance and severity of HPE-spectrum defects when exposed to low-dose teratogens — a model for the incomplete penetrance seen in human GLI2-mutation carriers and consistent with a genetic "second hit"/environmental modifier framework broadly invoked in HPE etiology.

3. Phenotypes

Because most human GLI2 mutation carriers present with the pituitary/polydactyly/facial phenotype rather than classic HPE, the phenotype list below spans that full spectrum, with HPO terms suggested.

Characteristics: - Age of onset: Congenital (structural/craniofacial and polydactyly features present at birth); pituitary hormone deficiencies often manifest neonatally (hypoglycemia, prolonged jaundice) or emerge through childhood as growth failure. - Severity/progression: Highly variable — from isolated cleft lip/palate with polydactyly at the mild end to semilobar HPE at the severe end. Endocrine deficits are typically stable but require lifelong hormone replacement; they are not degenerative. - Frequency among carriers — the defining feature is incomplete penetrance: In one key family study, of 11 parents carrying the same pathogenic GLI2 mutation as an affected proband, "only two had hypopituitarism and three had only polydactyly, while six were apparently completely normal," demonstrating that even severe loss-of-function alleles show markedly incomplete penetrance Roessler et al. 2003; summarized in Journal of Molecular Endocrinology 54(3):R141. - Quality of life impact: Untreated panhypopituitarism carries risk of adrenal crisis, severe hypoglycemia, and growth failure; with hormone replacement, endocrine outcomes are generally good. Craniofacial/limb anomalies may require surgical correction (cleft repair, polydactyly excision). Neurodevelopmental outcome tracks with brain structural involvement — normal-to-mild in isolated pituitary/polydactyly presentations, more impaired when frank HPE or seizures are present (Culler-Jones syndrome cohort).

4. Genetic/Molecular Information

Causal gene: GLI2 (GLI-Kruppel family member 2), OMIM 165230, HGNC:4318, located at chromosome 2q14.2. Human GLI2 protein contains an N-terminal transcriptional repressor domain and a C-terminal transcriptional activator domain; it binds DNA via C2H2 zinc-finger motifs* (ScienceDirect Topics: GLI2; PMID:10433919).

Variant classification and type: - Truncating variants (nonsense, frameshift, splice-site) that eliminate the C-terminal activator domain — the best-established pathogenic class, associated with pituitary anomalies, polydactyly, and the characteristic facial gestalt (midface hypoplasia, cleft lip/palate, hypotelorism) Corder et al. 2022. - Zinc-finger (DNA-binding domain) missense variants — also implicated in hypopituitarism per the same 2022 study title ("Truncating and zinc-finger variants in GLI2 are associated with hypopituitarism"). - Contiguous deletions spanning GLI2 at 2q14 — reported to produce milder HPE-spectrum phenotypes, occasionally with additional features (e.g., heterotaxy) attributable to deletion of neighboring genes PMID:22106008. - Synonymous and other missense variants are frequently identified but often classified benign/VUS — in the Bertolacini et al. 2012 cohort of 110 craniofacial-anomaly patients, 14 GLI2 variants were found (1 deletion, 1 insertion, 9 nonsynonymous, 3 synonymous), with only a subset (6 patients) judged possibly pathogenic PMID:21204792.

Functional consequence: Predominantly loss of function / haploinsufficiency. Roessler et al. functionally demonstrated that identified mutant alleles "lack GLI2 activity," establishing a functional link between GLI2 loss and the human phenotype PMID:14581620.

Somatic vs. germline: All reported HPE9/Culler-Jones variants are germline (constitutional), consistent with a developmental malformation syndrome; GLI2 is separately implicated in somatic oncogenic activation in some cancers (e.g., medulloblastoma, via Hedgehog pathway dysregulation), but that is mechanistically and clinically distinct from HPE9 and outside its scope.

Allele frequency: No population carrier-frequency data specific to pathogenic GLI2 HPE9 alleles were found in gnomAD-level detail in this search; given autosomal dominant inheritance with reduced penetrance and case-level/small-family reporting, pathogenic variants are expected to be very rare/private (population allele frequency approaching zero in large reference databases), consistent with ultra-rare disease status.

Modifier genes: No specific human modifier genes are validated for GLI2-HPE beyond the broader HPE "multiple-hit" model (interaction with other SHH-pathway gene variants, e.g., SHH, PTCH1, ZIC2, in trans, has been proposed in the general HPE genetics literature as contributing to phenotypic variability, though not GLI2-specific confirmed digenic cases in the sources reviewed here).

Epigenetic information: No GLI2-HPE9-specific DNA methylation or chromatin-modification data were identified in this search; GLI2 activity is regulated post-translationally (proteolytic processing/degradation is suppressed by active SHH signaling — PMID: PMC1447407, "Sonic hedgehog Signaling Regulates Gli2 Transcriptional Activity by Suppressing Its Processing and Degradation") rather than primarily by epigenetic mechanisms.

Chromosomal abnormalities: 2q14 microdeletions encompassing GLI2 are a recognized structural-variant cause, producing a phenotype continuous with point-mutation HPE9 (mild HPE-spectrum features, occasionally with contiguous-gene effects) PMID:22106008.

Suggested gene/ontology annotations: HGNC:4318 (GLI2); GO:0007224 (Smoothened signaling pathway); GO:0008589 (regulation of Smoothened signaling pathway); GO:0003700 (DNA-binding transcription factor activity); GO:0008270 (zinc ion binding, for the C2H2 zinc-finger domains).

5. Environmental Information

• Environmental factors: No GLI2-HPE9-specific toxin/pollutant exposure data identified; the general HPE environmental risk-factor literature (maternal diabetes, retinoic acid, cholesterol-synthesis-inhibiting drugs, alcohol) is the best proxy, and the mouse Gli2-haploinsufficiency/ethanol interaction study provides direct mechanistic support for gene-dose-dependent teratogen sensitivity relevant to GLI2 carriers specifically PMC3929747.
• Lifestyle factors: Maternal glycemic control in pregnancy is the most actionable modifiable factor relevant to the broader HPE spectrum, given the strong maternal-diabetes association.
• Infectious agents: None established for HPE or HPE9 specifically.

6. Mechanism / Pathophysiology

Molecular pathway: GLI2 acts as the principal transcriptional effector of the Sonic Hedgehog (SHH) signaling pathway (KEGG hsa04340; GO:0007224) in the ventral forebrain, craniofacial mesenchyme/first branchial arch, limb bud, and developing pituitary (Rathke's pouch). Canonical pathway logic:

1. Ligand-receptor step: In the absence of SHH ligand, the 12-pass transmembrane receptor PTCH1 inhibits accumulation and activity of SMO (Smoothened) in the primary cilium.
2. Ligand engagement: SHH binding to PTCH1 relieves this inhibition, allowing SMO to translocate into/accumulate within the primary cilium (a step also dependent on membrane cholesterol, which both modifies the SHH ligand post-translationally and licenses SMO activation) ScienceDirect: Patched, Smoothened and cholesterol.
3. GLI2 liberation: Active ciliary SMO drives dissociation of the SUFU–GLI2 repressive complex (with assistance from EVC/EVC2 at the ciliary base), releasing full-length GLI2 to enter the nucleus as a transcriptional activator of target genes including GLI1, PTCH1, and HHIP (a negative-feedback loop gene) PMID:20956384.
4. Bifunctional GLI2 processing: In the absence of SHH signal, GLI2 is partially proteolyzed into a truncated repressor form; SHH signaling suppresses this processing/degradation, tipping the balance toward the activator form PMC1447407.

Causal chain — genotype to phenotype: - Heterozygous truncating/loss-of-function GLI2 variant → GLI2 haploinsufficiency → reduced SHH-pathway transcriptional output in ventral forebrain midline, first branchial arch/craniofacial mesenchyme, limb bud (zone of polarizing activity-adjacent tissue), and Rathke's pouch/pituitary primordium → variably penetrant developmental field defects: - Ventral forebrain/midline: failure of prosencephalic cleavage in the most severe cases (classic HPE structural spectrum: alobar > semilobar > lobar > middle interhemispheric variant) — but in most GLI2 carriers, midline signaling is sufficient for cleavage and only subtler midfacial hypoplasia results. - Rathke's pouch/anterior pituitary: defective organogenesis → hypoplastic anterior pituitary, ectopic posterior pituitary lobe, panhypopituitarism. - Limb bud (postaxial zone): postaxial polydactyly, reflecting a role for GLI2/SHH signaling in anteroposterior limb patterning distinct from (and postaxial rather than the SHH/GLI3-ZRS preaxial pattern typical of ZRS-associated syndromes). - First branchial arch derivatives: mandibular hypoplasia, ear anomalies, cleft lip/palate, TMJ anomalies. - Incomplete penetrance is best explained mechanistically by the mouse gene-environment model: a single functional GLI2 allele provides sufficient pathway output for normal development under baseline conditions, but reduced buffering capacity renders development vulnerable to additional genetic or environmental "second hits" (teratogen exposure, stochastic developmental variation, possible modifier alleles in other pathway genes) PMID:27585885.

Cellular processes: Neural progenitor patterning/ventralization in the neural tube and forebrain (GO:0021871, "morphogenesis of embryonic epithelium," and GO:0021854, "hypothalamus development," among relevant GO terms); craniofacial neural crest cell patterning; anterior pituitary progenitor (Rathke's pouch) proliferation and differentiation; limb bud mesenchymal patterning.

Protein dysfunction: Predominantly loss-of-function/haploinsufficiency — truncated proteins lacking the C-terminal activator domain fail to drive SHH target-gene transcription; some act with residual repressor activity, potentially producing partial dominant-negative effects, though most literature frames the mechanism as simple haploinsufficiency.

Tissue damage mechanism: Not applicable in the classic "tissue injury" sense — this is a developmental patterning defect, not a degenerative or destructive process; the pathology is one of failed morphogenesis rather than secondary tissue injury (with the caveat that untreated endocrine deficiency can secondarily cause metabolic tissue stress, e.g., hypoglycemic injury).

Suggested GO/CL/UBERON terms for pathophysiology modeling: - GO:0007224 Smoothened signaling pathway - GO:0021871 forebrain regionalization / GO:0021983 pituitary gland development - GO:0060173 limb development / GO:0060174 limb bud formation - CL:0002573 Schwann cell (not directly relevant) — more relevant: CL:0000710 neurectodermal cell / CL:0002028 basal cell of epithelium of Rathke's pouch (if available) / generic "neural progenitor cell" CL:0011020 - UBERON:0002298 brainstem / UBERON:0001891 midbrain (less relevant); most relevant: UBERON:0002264 pars distalis of adenohypophysis, UBERON:0002037 cerebellum (not affected); primary sites: UBERON:0000955 brain (forebrain/prosencephalon), UBERON:0000007 pituitary gland, UBERON:0002544 pharyngeal arch (first branchial arch), UBERON:0002544 limb bud/UBERON:0004357 hand

7. Anatomical Structures Affected

Organ level: - Primary: Brain (forebrain/prosencephalon — in the minority with true HPE); pituitary gland (anterior and posterior lobes); craniofacial skeleton (midface, mandible, maxilla); limbs (hands/feet — postaxial polydactyly). - Secondary/complication-related: Endocrine organs downstream of pituitary hormone axes (thyroid, adrenal glands, gonads) secondary to central hormone deficiency; eyes (hypotelorism, occasionally more severe ocular anomalies in classic HPE); ears (external ear malformations, pre-auricular tags); oral cavity (cleft lip/palate). - Body systems: Nervous system (CNS structural, and secondary seizures/intellectual disability), endocrine system (primary target of the pituitary-anomaly arm), musculoskeletal system (craniofacial, limb).

Tissue/cell level: - Ventral forebrain neuroepithelium and midline glial structures (in classic HPE cases) - Rathke's pouch epithelium / anterior pituitary hormone-secreting cell lineages (somatotropes, corticotropes, thyrotropes, gonadotropes — reflecting the multi-hormone deficiency pattern) - Cranial neural crest-derived craniofacial mesenchyme - Limb bud mesenchyme (postaxial zone) - Temporomandibular joint condylar/coronoid cartilage (a specifically noted GLI2-associated finding)

Subcellular level: Primary cilium (site of SMO/SUFU/GLI2 pathway transduction — GO:0005929 cilium; GO:0060170 ciliary membrane); nucleus (site of GLI2 transcriptional activity); cytoplasm (site of GLI2 proteolytic processing).

Localization/laterality: HPE-spectrum brain and facial anomalies are typically midline defects (bilateral, symmetric, affecting the axis of embryonic cleavage) rather than lateralized; postaxial polydactyly may be unilateral or bilateral and can affect hands, feet, or both.

8. Temporal Development

• Onset: Congenital for all structural (craniofacial, limb, brain) features; pituitary hormone deficiencies may be apparent at birth (neonatal hypoglycemia, cholestatic jaundice from cortisol/GH deficiency, micropenis) or emerge over infancy/childhood as growth failure or delayed puberty becomes evident.
• Onset pattern: Structural anomalies are fixed at birth (non-progressive congenital malformations); endocrine deficits, while congenital in origin (structural pituitary maldevelopment), may have an insidious, delayed-recognition clinical onset if hormone deficiency is partial or evolves.
• Disease stages: Not applicable in the sense of a staged progressive disease — HPE9/Culler-Jones syndrome is a static congenital malformation/endocrinopathy rather than a degenerative condition.
• Progression rate/course: Structural features are stable (non-progressive) from birth; hormone deficiencies, once established, are generally lifelong and stable with replacement therapy, though evolving multi-hormone deficiency over childhood (e.g., isolated GH deficiency progressing to panhypopituitarism) has been described in the broader hypopituitarism literature and is plausible in GLI2 cases.
• Duration: Chronic, lifelong (endocrine and structural sequelae persist; surgical corrections of cleft/polydactyly are one-time interventions).
• Remission: Not applicable — this is a structural/developmental condition, not a relapsing-remitting disease.
• Critical periods: The relevant "critical period" is prenatal — first-trimester forebrain, craniofacial, pituitary (Rathke's pouch), and limb bud patterning windows, during which GLI2 haploinsufficiency (potentially compounded by environmental "second hits" such as maternal hyperglycemia, retinoic acid, or alcohol exposure) determines phenotypic severity.

9. Inheritance and Population

Epidemiology: - Holoprosencephaly overall occurs in ~1 in 250 conceptuses but only ~1 in 8,000–16,000 live births (most affected conceptuses are lost to spontaneous abortion); reported live-birth prevalence ranges 0.48–1.70 per 10,000 across international birth-defect surveillance systems, with a large Chinese national study finding 0.92 per 10,000 (1,222 cases / 13,284,142 births) (PMC6553724; StatPearls NBK560861). - GLI2 is a minor contributor to this overall HPE burden (<1% of classic HPE cases attributable to GLI2 point mutations), but is disproportionately represented among patients specifically ascertained for congenital hypopituitarism with polydactyly — making HPE9/Culler-Jones syndrome an important, likely underdiagnosed cause of syndromic congenital hypopituitarism. - Exact prevalence/incidence figures specific to HPE9 (as opposed to HPE overall) are not separately tabulated in Orphanet/OMIM; it should be treated as an ultra-rare disorder (likely well under 1:1,000,000, per case-series-level reporting to date).

Inheritance pattern: Autosomal dominant, with the defining features of incomplete penetrance and variable expressivity. GeneReviews explicitly notes that "[b]ecause incomplete penetrance is a feature of dominantly inherited HPE, relatively normal facial appearance can be seen in individuals who have causative gene variants and affected first degree relatives" (NBK1530).

Penetrance: Markedly incomplete — in the Roessler et al. family study, only 2/11 mutation-carrying parents had hypopituitarism, 3/11 had isolated polydactyly, and 6/11 were phenotypically normal despite carrying the identical pathogenic variant as their affected child. This is among the most striking documented penetrance figures in the monogenic HPE literature and is a key curation point.

Expressivity: Highly variable, spanning isolated polydactyly → isolated pituitary anomaly → combined craniofacial/pituitary/limb phenotype (Culler-Jones syndrome) → rare semilobar HPE.

Germline mosaicism: Not specifically documented for GLI2 in the sources reviewed, though plausible given the general dominant-inheritance, incomplete-penetrance pattern typical of HPE genes; a documented mother-and-two-daughters case series with a GLI2 deletion explicitly demonstrates "variable expressivity and incomplete penetrance" across generations (PMC7669391), consistent with vertical transmission through a mildly/subclinically affected parent.

Founder effects / consanguinity: No founder mutations or consanguinity-driven recessive component identified — consistent with autosomal dominant, not recessive, inheritance.

Carrier frequency: Not established/reported; expected to be very low given rarity and predominance of de novo or small-family case reporting.

Population demographics: No specific ethnic or geographic enrichment reported for GLI2-HPE9 itself; broader HPE literature notes higher reported (ascertainment-influenced) prevalence in some populations (African-American, Hispanic, Pakistani communities in the US) attributable to differential rates of prenatal diagnosis/termination rather than true differential incidence. Sex ratio and age-distribution data specific to HPE9 were not identified in this search.

10. Diagnostics

Clinical/laboratory tests: - Endocrine hormone panels: GH, IGF-1, cortisol/ACTH, TSH/free T4, gonadotropins (LH/FSH), prolactin — to characterize the pattern and completeness of multiple pituitary hormone deficiency (MPHD). - Electrolytes/urine osmolality/water-deprivation testing — for suspected diabetes insipidus (posterior pituitary/ADH axis).

Imaging: - Brain/pituitary MRI is the key diagnostic imaging modality. Characteristic findings in GLI2-mutation carriers with hypopituitarism: hypoplastic anterior pituitary with an ectopic posterior pituitary lobe (pituitary stalk interruption-like pattern), often without any HPE brain malformation — this pattern was specifically demonstrated in 4 evaluated patients with GLI2 mutations PMID:20685856; a further case report describes "Ectopic Posterior Pituitary, Polydactyly, Midfacial Hypoplasia and Multiple Pituitary Hormone Deficiency due to a Novel Heterozygous... Mutation in the GLI2 Gene" (PMC7499131). - In more severely affected individuals: MRI may show semilobar or lobar HPE (fused thalami, absent septum pellucidum, monoventricle, absent/hypoplastic corpus callosum, absent olfactory bulbs). - Skeletal imaging for polydactyly characterization prior to surgical planning.

Genetic testing: - Single-gene GLI2 sequencing (all coding exons) is commercially available (e.g., GTR test 583574; PreventionGenetics HPE9/GLI2 panel). - HPE gene panels (typically including SHH, ZIC2, SIX3, TGIF1, PTCH1, GLI2, and others) are the standard first-tier approach given genetic heterogeneity of HPE. - Whole-exome/genome sequencing is increasingly used, especially for atypical/expanded phenotypes ("Exome sequencing improves genetic diagnosis of congenital orofacial clefts" PMC10512413; a 2025 case report describes a de novo GLI2 missense variant identified via exome sequencing in isolated hypopituitarism with craniofacial anomalies). - Chromosomal microarray (CMA) is indicated when a contiguous 2q14 deletion is suspected (larger phenotype, additional features beyond the classic GLI2 point-mutation presentation). - Familial cascade testing is important given documented incomplete penetrance — apparently unaffected parents of a proband may carry the variant and should be counseled that normal phenotype does not exclude carrier status.

Clinical diagnostic criteria: No formal consensus diagnostic criteria specific to HPE9 exist; diagnosis rests on the combination of (a) characteristic phenotype (pituitary anomaly ± polydactyly ± midfacial hypoplasia ± cleft lip/palate, with or without HPE), and (b) confirmatory GLI2 molecular finding. Differential diagnosis includes other HPE-spectrum genes (SHH, ZIC2, SIX3, TGIF1, PTCH1), other syndromic causes of congenital hypopituitarism with polydactyly (e.g., Pallister-Hall syndrome, GLI3-related — a related GLI-family gene with an analogous polydactyly/hypothalamic hamartoma phenotype and important genetic differential), and Smith-Lemli-Opitz syndrome (cholesterol synthesis defect that phenocopies SHH-pathway disruption).

Screening: No population-based newborn screening program targets HPE9 specifically; prenatal ultrasound may detect structural HPE brain findings and polydactyly, prompting targeted prenatal genetic testing in known-carrier families.

11. Outcome/Prognosis

• Survival/mortality: Prognosis is highly dependent on phenotypic severity. Isolated polydactyly or isolated mild pituitary anomaly carries an excellent prognosis with normal life expectancy. Severe (semilobar/alobar) HPE carries the poor prognosis characteristic of classic HPE generally (high perinatal/infant mortality in severe forms), but this is uncommon among GLI2 carriers specifically (only ~1/43 truncating-variant carriers had frank HPE in the reviewed literature).
• Morbidity: Untreated panhypopituitarism carries risk of life-threatening adrenal crisis and hypoglycemia, particularly in the neonatal period; with recognition and hormone replacement, morbidity is substantially reduced and outcomes approach those of other causes of congenital hypopituitarism.
• Complications: Adrenal crisis, severe hypoglycemia (especially neonatal), growth failure if GH deficiency undiagnosed, hypogonadism/delayed puberty, feeding/speech difficulties from cleft palate, functional limb impairment from polydactyly (usually correctable surgically).
• Recovery potential: Structural anomalies are permanent (surgical correction, not cure); endocrine deficiencies are fully manageable (not curable) with lifelong hormone replacement — patients on adequate replacement generally achieve normal growth and pubertal development.
• Prognostic factors: Presence and severity of brain structural HPE is the dominant prognostic determinant; truncating (vs. missense) GLI2 variants correlate with more complete/severe pituitary and polydactyly phenotypes per the Corder et al. 2022 genotype-phenotype analysis.

12. Treatment

There is no disease-modifying or curative treatment for the underlying GLI2 developmental defect; management is multidisciplinary and supportive/replacement-based.

Pharmacotherapy (hormone replacement — the mainstay of management): - Growth hormone (recombinant human GH) for GH deficiency — MAXO term: consider MAXO:0000950 (supportive care) or a specific pharmacotherapy term paired with therapeutic_agent (somatropin; NCIT term for recombinant human growth hormone). - Hydrocortisone replacement for ACTH/cortisol deficiency (critical for preventing adrenal crisis). - Levothyroxine for central hypothyroidism (TSH deficiency). - Desmopressin (DDAVP) for central diabetes insipidus. - Sex hormone replacement (testosterone or estrogen/progesterone) at puberty for hypogonadotropic hypogonadism.

Surgical/interventional: - Polydactyly excision/reconstructive surgery — MAXO:0000004 (surgical procedure) / NCIT:C15329 (Surgical Procedure), often orthopedic (NCIT:C16186, Orthopedic Surgical Procedure). - Cleft lip/palate repair — standard craniofacial surgical protocol. - Craniofacial reconstructive surgery as needed for midfacial hypoplasia/TMJ anomalies.

Supportive/rehabilitative care: - Early developmental intervention, physical/occupational/speech therapy as indicated by neurodevelopmental status (MAXO:0000011 physical therapy; MAXO:0000930 speech therapy). - Nutritional support in infancy, particularly for feeding difficulty related to cleft palate or hypoglycemia risk.

Genetic counseling: MAXO:0000079 (genetic counseling) is essential given autosomal dominant inheritance with incomplete penetrance — counseling must explicitly address the possibility of a phenotypically normal or minimally affected (isolated polydactyly) parent carrying the causal variant, given the well-documented penetrance data above.

Experimental/targeted therapies: No GLI2-pathway-targeted or gene therapy approaches were identified as being in clinical development for HPE9 specifically. (Hedgehog-pathway small-molecule inhibitors such as SMO inhibitors exist for cancer indications — e.g., basal cell carcinoma, medulloblastoma — but these target pathway hyperactivation and are not relevant to this loss-of-function developmental disorder; no gain-of-function/agonist strategy for GLI2 haploinsufficiency was found reported.)

Treatment strategy: Management follows a standard congenital hypopituitarism algorithm (endocrinology-led, with hormone deficiencies identified and replaced sequentially/simultaneously as diagnosed) combined with craniofacial/orthopedic surgical planning for structural anomalies — essentially the same clinical pathway used for other genetic causes of congenital hypopituitarism with polydactyly (e.g., Pallister-Hall syndrome).

13. Prevention

• Primary prevention: No primary prevention exists for the germline GLI2 mutation itself. For the environmentally-modulated component of the broader HPE spectrum, optimizing maternal glycemic control in diabetic pregnancies is the most evidence-supported modifiable primary-prevention measure; avoidance of retinoic acid excess and cholesterol-synthesis-inhibiting medications in pregnancy is also generally advised in the broader HPE prevention literature.
• Secondary prevention (early detection): Newborn screening for hypoglycemia/jaundice in infants with any suggestive dysmorphic features (polydactyly + midfacial hypoplasia) should prompt early endocrine evaluation to prevent adrenal-crisis morbidity — this is the single most impactful secondary-prevention measure for GLI2-HPE9, given that endocrine complications (not structural anomalies) drive acute morbidity/mortality risk.
• Genetic screening: Prenatal diagnosis via targeted GLI2 testing is available in families with a known pathogenic variant; given incomplete penetrance, genetic counseling must clarify that a negative family history in parents does not reduce recurrence risk if a parent is an unrecognized (subclinical) carrier.
• Tertiary prevention: Lifelong monitoring and hormone-replacement adjustment to prevent complications of under- or over-replacement (e.g., adrenal crisis prevention via stress-dosing education, growth monitoring on GH therapy).
• Public health/behavioral: No population-level public health intervention specific to HPE9 exists; general periconceptional counseling regarding diabetes control and teratogen avoidance applies to the broader HPE risk-reduction framework.

14. Other Species / Natural Disease

• Taxonomy: Mouse (Mus musculus, NCBITaxon:10090) is the dominant model species; Gli2 is also studied in zebrafish (Danio rerio, NCBITaxon:7955) in the broader Hedgehog-signaling/craniofacial development literature, though HPE9-specific zebrafish models were not identified in this search.
• Orthologous gene: Mouse Gli2 (MGI:95728), NCBI Gene ID 14633 (mouse); highly conserved zinc-finger transcription factor with essentially identical domain architecture and pathway role as human GLI2.
• Natural disease in other species: No naturally occurring GLI2-mutant HPE has been reported in companion animals or wildlife in the sources reviewed (this is a modeled/engineered-mutation disease in animals, not a spontaneously occurring veterinary condition, unlike some other Mendelian disorders with OMIA entries).
• Comparative pathology: Mouse Gli2 null homozygotes show floor-plate absence, foregut/lung/anorectal defects, skeletal malformations, and altered commissural neuron guidance, with most dying before E18.5 (MGI:95728). Background-strain-dependent HPE recapitulation is a key comparative-biology point (see Model Organisms below).

15. Model Organisms

• Mouse Gli2 knockout (constitutive null): Homozygous Gli2-null mice are embryonic lethal (most die before E18.5) with absence of the neural tube floor plate, foregut/lung/anorectal defects, skeletal malformations, and altered commissural neuron axon guidance (MGI:95728).
• Genetic-background dependence — a key model insight: On the C57BL/6J background, homozygous Gli2 loss-of-function recapitulates the characteristic brain and facial features of severe human HPE, including midfacial hypoplasia, hypotelorism, and medial forebrain deficiency with loss of ventral neurospecification. In contrast, Gli2-null mice on an outbred CD-1 background do not recapitulate the forebrain/facial HPE phenotype — directly demonstrating background-dependent modifier effects on HPE penetrance/expressivity, a strong parallel to the incomplete penetrance seen in human GLI2 carriers.
• Heterozygous (haploinsufficient) mice as the more clinically relevant model: Gli2+/− heterozygous mice are phenotypically normal at baseline, closely mirroring the incompletely penetrant human carrier state, but show increased penetrance and severity of HPE-spectrum defects upon low-dose teratogen exposure — the key gene-environment interaction model for this disease (PMID:27585885; PMC5117230).
• Ethanol-exposure model: Gli2 (and Shh) haploinsufficient mice show exacerbated teratogenic response to prenatal ethanol exposure, directly modeling a gene × alcohol-exposure interaction relevant to the "second hit" hypothesis for incomplete penetrance in human carriers (PMC3929747).
• Model limitations: Because complete phenotype recapitulation (forebrain/facial HPE) requires both homozygous loss and a permissive (C57BL/6J) genetic background, no single mouse model directly represents the typical human HPE9 situation (heterozygous variant, phenotype ranging from normal to severe). The heterozygous + teratogen-challenge paradigm is the best available proxy for the human clinical reality of incomplete penetrance and gene-environment-dependent expressivity.
• Applications: These models are used to study SHH-pathway dosage sensitivity in forebrain/craniofacial/pituitary/limb patterning, to dissect genetic-background modifier effects on penetrance, and to test specific environmental teratogen interactions (diabetes-like hyperglycemia models, retinoic acid, ethanol, cholesterol-pathway inhibitors) relevant to human risk-factor counseling.
• Resources: MGI (Mouse Genome Informatics) — Gli2 gene page MGI:95728; specific targeted allele MGI:2158720.

Summary of Key Curation Points for a Dismech Entry

1. Two-tier phenotype framing is essential: HPE9 nominally denotes GLI2-caused HPE, but the dominant, best-evidenced human phenotype is the pituitary anomaly + postaxial polydactyly + subtle facial features presentation (formally split out as Culler-Jones syndrome, OMIM #615849) — true brain-cleavage HPE is a minority presentation in GLI2 carriers (~1/43 truncating-variant carriers). A dismech entry should model this spectrum explicitly, likely with has_subtypes distinguishing the classic-HPE-with-forebrain-cleavage presentation from the pituitary/polydactyly-predominant presentation, and should consider cross-referencing/coordinating with a separate Culler-Jones syndrome entry if one exists or is planned (grouping candidate).
2. Incomplete penetrance is the single most citable, well-quantified fact (Roessler 2003: 2/11 hypopituitarism, 3/11 isolated polydactyly, 6/11 unaffected among mutation-carrying parents) — ideal for the Inheritance block and for genetic-counseling notes.
3. Mechanism module fit: This disease is a strong candidate for conforms_to a Sonic Hedgehog / GLI2-pathway–anchored pathophysiology node (SUFU-GLI2 dissociation → nuclear GLI2 activator function → target-gene transcription in forebrain/pituitary/limb/craniofacial primordia), and pairs naturally with the mouse gene-environment (Gli2 haploinsufficiency × teratogen) model as HUMAN_MODEL_MISMATCH/mechanistic-hypothesis material explaining penetrance variability.
4. Primary citable sources: Roessler et al. 2003 (PMID:14581620, founding paper), Bertolacini et al. 2012 (PMID:21204792, phenotypic variability cohort), Corder et al. 2022 (AJMG-A, genotype-phenotype truncating vs. zinc-finger), and the 2010 PubMed:20685856 imaging paper are the core human-clinical evidence base; PMID:27585885 and PMC3929747 are the core model-organism (MODEL_ORGANISM evidence_source) sources for the gene-environment mechanism.

Sources: - Entry - #610829 - HOLOPROSENCEPHALY 9; HPE9 - OMIM - Entry - *165230 - GLI-KRUPPEL FAMILY MEMBER 2; GLI2 - OMIM - Entry - #615849 - CULLER-JONES SYNDROME; CJS - OMIM - Holoprosencephaly Overview - GeneReviews - NCBI Bookshelf (NBK1530) - Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features - PubMed (PMID:14581620) - Clinical findings in patients with GLI2 mutations – phenotypic variability - PMC (PMID:21204792) - Truncating and zinc‐finger variants in GLI2 are associated with hypopituitarism - Corder et al. 2022 - AJMG-A - Novel heterozygous nonsense GLI2 mutations in patients with hypopituitarism and ectopic posterior pituitary lobe without holoprosencephaly - PubMed (PMID:20685856) - Ectopic Posterior Pituitary, Polydactyly, Midfacial Hypoplasia and MPHD due to a Novel GLI2 Mutation - PMC - A patient with a mild holoprosencephaly spectrum phenotype and heterotaxy and a 1.3 Mb deletion encompassing GLI2 - PubMed (PMID:22106008) - Role of GLI2 in hypopituitarism phenotype - Journal of Molecular Endocrinology - Case Report: A case of Culler-Jones syndrome caused by GLI2 gene mutation - Frontiers/PMC - A case series of a mother and two daughters with a GLI2 gene deletion demonstrating variable expressivity and incomplete penetrance - PMC - Gli2 gene-environment interactions contribute to the etiological complexity of holoprosencephaly: evidence from a mouse model - PMC (PMID:27585885) - The Teratogenic Effects of Prenatal Ethanol Exposure Are Exacerbated by Sonic Hedgehog or Gli2 Haploinsufficiency in the Mouse - PMC - Gli2 MGI Mouse Gene Detail - MGI:95728 - Sonic hedgehog Signaling Regulates Gli2 Transcriptional Activity by Suppressing Its Processing and Degradation - PMC - A mechanism for vertebrate Hedgehog signaling: recruitment to cilia and dissociation of SuFu-Gli protein complexes - PubMed - The interplay of Patched, Smoothened and cholesterol in Hedgehog signaling - ScienceDirect - Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain - PubMed (PMID:10433919) - Epidemiological characteristics of holoprosencephaly in China, 2007-2014 - PMC - Holoprosencephaly - StatPearls - NCBI Bookshelf (NBK560861) - Holoprosencephaly: Review of Embryology, Clinical Phenotypes, Etiology and Management - MDPI Children - The unfolding clinical spectrum of holoprosencephaly due to mutations in SHH, ZIC2, SIX3 and TGIF genes - EJHG - Holoprosencephaly 9 - MalaCards - NM_001374353.1(GLI2):c.4612T>C (p.Ser1538Pro) AND Holoprosencephaly 9 - ClinVar